Gigabac

Colistimethate is an antibiotic used to treat certain bacterial infections. It works by stopping the growth of bacteria.

Antibiotic

Colistimethate is a surface active agent which penetrates into and disrupts the bacterial cell membrane. Colistimethate is polycationic and has both hydrophobic and lipophilic moieties. It interacts with the bacterial cytoplasmic membrane, changing its permeability. This effect is bactericidal. There is also evidence that polymyxins enter the cell and precipitate cytoplasmic components, primarily ribosomes.

Susceptible Infections Dosage expressed in terms of colistin base 2.5-5 mg/kg/day divided q6-12hr IV/IM; not to exceed 5 mg/kg/day

Colistimethate Sodium Altan should not be given with certain antibiotics like- aminoglycosides and polymyxin due to report of interfere with the nerve transmission at the neuromuscular junction. It should not be given with muscle relaxants e.g., tubocurarine and other drugs including ether, succinylcholine, gallamine, decamethonium and sodium citrate. The concomitant use of Sodium Cephalothin and Colistimethate Sodium Altan should be avoided.

Contraindications Hypersensitivity Precaution Do not exceed 5 mg/kg/day (as colistin base) with normal renal function (see Dosing for renal impairment) Not indicated for infections by Proteus or Neisseria (most strains are resistant) Risk of nephrotoxicity, neurotoxicity; discontinue if elevated BUN/creatinine Risk of respiratory arrest in myasthenia gravis or concomitant anesthetics or neuromuscular blocking drugs Risk of C. difficile-associated pseudomembranous colitis Sedative effects may impair driving, operating machinery

Dizziness, Paresthesia, Tingling of extremities and tongue, Neurotoxicity, Nephrotoxicity, Acute respiratory failure, Respiratory tract paralysis, Slurred speech, Vertigo, Seizures, Anaphylaxis

Colistimethate sodium should be used in pregnancy only if the benefit to the mother outweighs the potential risk to the fetus. Colistimethate sodium is secreted in breast milk. Colistimethate sodium should be administered to breastfeeding women only when clearly needed.

Overdosage with Colistimethate Sodium Altan Sodium Altan can cause neuromuscular blockade characterized by paresthesia, lethargy, confusion, dizziness, ataxia, nystagmus, disorders of speech and apnea. Respiratory muscle paralysis may lead to apnea, respiratory arrest and death. Overdosage with the drug can also cause acute renal failure, manifested as decreased urine output and increases in serum concentrations of B.U.N and creatinine. As in any case of overdose, Colistimethate Sodium Altan Sodium Altan therapy should be discontinued and general supportive measures should be utilized.

Before reconstitution: Store below 30°C. After reconstitution: Store at 2°C to 8°C (Do not freeze) and use within 24 hours.

P© L©

Each vial contains Colistimethate Sodium 1 MIU or 34 mg Colistin. Each vial contains Colistimethate Sodium 2 MIU or 68 mg Colistin. Each vial contains Colistimethate Sodium 3 MIU or 102 mg Colistin. Each vial contains Colistimethate Sodium 4.5 MIU or 150 mg Colistin.